阿德福韦酯联合胸腺肽α_1治疗拉米夫定耐药慢性乙肝的临床研究

Clinical study of adefovir dipivoxil combined with thymosin α1 on treatment of lamivudine-resistant chronic hepatitis B

目的:探讨阿德福韦酯联合胸腺肽α1治疗拉米夫定耐药慢性乙肝的临床疗效。方法:将本院2007年1月～2011年9月158例拉米夫定耐药慢性乙肝患者随机分为两组,单独采用阿德福韦酯(10mg/d,连用48周)治疗的患者作为对照组78例,采用阿德福韦酯(10mg/d,连用48周)联合胸腺肽α1(皮下注射1.6mg/次,每周2次,连续治疗48周)治疗的患者作为观察组80例,分别检测患者各项指标并进行比较分析。结果:观察组ALT复常情况、HBV-DNA转阴情况、HBeAg转阴情况、HBe血清转换情况在治疗后24周和治疗后48周均明显好于对照组,差异有统计学意义(P<0.05)。结论:阿德福韦酯联合胸腺肽α1治疗拉米夫定耐药慢性乙肝的临床疗效显著,值得临床广泛推广。

Objectives： To investigate the clinical curative effect in adefovir dipivoxil combined with thymosin α1 in the treatment of lamivudine-resistant chronic hepatitis B. Methods： One huandred and fifty eight patients in our hospital from January 2007 to September 2011 with lamivudine resistance in chronic hepatitis B were randomly divided into 2 groups, used separate adefovir dipivoxil （10 mg/d, continuous treatment for 48 weeks） treatment of patients as control group of 78 cases, with adefovir dipivoxil （10 mg/d, continuous treatment for 48 weeks） combined with thymosin α1 （subcutaneous injection of 1.6 mg/time, 2 times a week, continuous treatment for 48 weeks） treatment of the patient as the observation group of 80 cases, were detected in patients with each index and comparative analysis. Results： The observation group ALT recovery, HBV-DNA negative cases, HBeAg negative cases, HBe seroconversion in patients after 24 weeks and 48 weeks treatment was significantly better than the control group, there was significant difference （P0.05）. Conclusion： Adefovir dipivoxil combined with thymosin α1 in treatment of lamivudine-resistant chronic hepatitis B has curative clinical effect, is worthy of clinical application.